Key result
PVI plus renal denervation cuts 12-month AF recurrence by ~56% vs PVI alone.
Why the study?
Renal denervation controls blood pressure in drug-resistant hypertension, but its effect on atrial fibrillation in patients undergoing pulmonary vein isolation was unknown.
RCT (n=27)
randomized
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“While this was a small study consisting of only 27 patients it definitely highlights the potential of this new therapy. In this study, patients with symptomatic paroxysmal or persistent AF refractory to antiarrhythmic drugs and drug-resistant hypertension which was defined as systolic blood pressure >160 mmHg despite triple antihypertensive drug therapy were enrolled in this study. The one-year success rate was 69% in the AF ablation and renal denervation group versus just 29% in the AF ablation only group. Clearly, renal denervation dramatically improved the success rate of AF ablation in this pilot study.”
“Hypertension is one of the most prevalent risk factors for developing AF, but we've seen that it is also potentially the most modifiable risk factor for halting the progression of the disease. As we continue to look for ways to prevent AF recurrence and improve outcomes for patients with AF, this trial may reveal a potential new treatment path for patients.”
Supports adding renal denervation to PVI in resistant hypertension with AF; extends sympathetic modulation evidence from this RCT.
OBJECTIVES: The aim of this prospective randomized study was to assess the impact of renal artery denervation in patients with a history of refractory atrial fibrillation (AF) and drug-resistant hypertension who were referred for pulmonary vein isolation (PVI). BACKGROUND: Hypertension is the most common cardiovascular condition responsible for the development and maintenance of AF. Treating drug-resistant hypertension with renal denervation has been reported to control blood pressure, but any effect on AF is unknown. METHODS: Patients with a history of symptomatic paroxysmal or persistent AF refractory to ≥2 antiarrhythmic drugs and drug-resistant hypertension (systolic blood pressure >160 mm Hg despite triple drug therapy) were eligible for enrolment. Consenting patients were randomized to PVI only or PVI with renal artery denervation. All patients were followed ≥1 year to assess maintenance of sinus rhythm and to monitor changes in blood pressure. RESULTS: Twenty-seven patients were enrolled, and 14 were randomized to PVI only, and 13 were randomized to PVI with renal artery denervation. At the end of the follow-up, significant reductions in systolic (from 181 ± 7 to 156 ± 5, p < 0.001) and diastolic blood pressure (from 97 ± 6 to 87 ± 4, p < 0.001) were observed in patients treated with PVI with renal denervation without significant change in the PVI only group. Nine of the 13 patients (69%) treated with PVI with renal denervation were AF-free at the 12-month post-ablation follow-up examination versus 4 (29%) of the 14 patients in the PVI-only group (p = 0.033). CONCLUSIONS: Renal artery denervation reduces systolic and diastolic blood pressure in patients with drug-resistant hypertension and reduces AF recurrences when combined with PVI.
No takes yet. Share an insight, caveat, or question.
Pokushalov et al. (2012) conducted an RCT in Refractory symptomatic atrial fibrillation and resistant hypertension (n=27). Pulmonary vein isolation with renal artery denervation vs. Pulmonary vein isolation only was evaluated on Maintenance of sinus rhythm (AF-free at 12 months) (p=0.033). Pulmonary vein isolation combined with renal artery denervation increased the proportion of patients remaining AF-free at 12 months compared to PVI alone.
Synapse has enriched 10 related papers. Consider them for comparative context: